Talha Ahmed11, Ayesha Safdar2, Sahar Fatima3, Iqbal Ratnani33 and Salim Surani4*
1Department of Medicine, University of Maryland, USA
2Department of Medicine, Army Medical College, Pakistan
3Department of Critical Care and Anesthesiology, Houston Methodist Hospital
4Department of Medicine, Texas A and M University, Texas
*Corresponding Author: Salim Surani, Department of Medicine, Texas A and M University, Texas.
Received: January 17, 2020; Published: January 27, 2020
SGLT2: Sodium-Glucose Cotransporter 2 Inhibitors; FDA: Food And Drug Administration; MACE: Major Adverse Cardiovascular Events; HFREF: Heart Failure With Reduced Ejection Fraction; ICD: Implantable Cardioverter Defibrillator; CRT: ACC/AHA/HFSA: Cardiac Resynchronization Therapy; American College Of Cardiology/American Heart Association/Heart Failure Society Of America; HFPEF: Heart Failure With Preserved Ejection Fraction.
The recently published trial, the DAPA-HF trial, advocating the use of Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure with reduced ejection fraction (HFrEF) has raised some questions and concerns regarding the gaps in clinical trials and real world situation faced by the patients and providers . At one hand, the medication proved to have a beneficial effect in the form of mortality reduction and reduced heart failure hospitalization in this large, phase III clinical trial. On the other hand, issues related to its cost, insurance approval, risk of polypharmacy (when used with other heart failure medications) arose. Moreover, where it fits in the spectrum of guideline directed medical therapy (GDMT) is also an important question that needs to be addressed in order to bridge the gap between the benefits seen in clinical trial and real-world situation.
Citation: Salim Surani., et al. “Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure; So Close Yet So Far". Acta Scientific Medical Sciences 4.2 (2020): 198-200.
Copyright: © 2020 Salim Surani., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.